MarketCapExport financials
GoodRx Holdings (GDRX)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
GoodRx Holdings Income Statement 2025-2011 | GDRX
Brief overview of financial results at GoodRx Holdings
The comparison covers a five-year financial horizon. GoodRx Holdings reported revenue of 551 million dollars in 2020 and 797 million dollars by 2025. The total change was +44.7%, with a CAGR of approximately 7.7%. The direction is positive, but the growth rate is not particularly high.
At the gross-profit level, the result moved from $521 million to $739 million, a change of +41.9%. Cost of revenue developed less favorably than sales and pressured gross profitability. Comparing the endpoints gives gross margins of 94.6% and 92.8%. The economics of the core business remained steady.
Over the period, EBITDA shifted from −257 million dollars to 173 million dollars, a change of +167.1%. Operating profitability strengthened faster than the scale of sales. The EBITDA share of revenue changed from −46.7% to 21.7%. Higher profitability strengthens the quality of operating growth.
Net income moved from −294 million dollars at the start to 30.4 million dollars at the end. The business moved out of a loss and ended the period with a profit.
Market capitalization changed from $16.4 billion to $1.4 billion (−91.7%). Financial performance is stronger than the share-price trend.
Overall conclusion
The results present an uneven picture without one dominant signal. The constructive conclusion rests on an improving EBITDA margin, sales growth and improving net profitability. The most visible risks are a weaker market valuation and a lower gross margin. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.
Annual Income Statement GoodRx Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
1.36 B | 1.95 B | 3.26 B | 3.28 B | 11.2 B | 16.4 B | - | - | - | - | - | - | - | - | - |
Shares |
356 M | 386 M | 410 M | 413 M | 410 M | 275 M | - | - | - | - | - | - | - | - | - |
Historical Prices |
3.82 | 5.05 | 7.94 | 7.94 | 27.4 | 44.5 | - | - | - | - | - | - | - | - | - |
Net Income |
30.4 M | 16.4 M | -8.9 M | -32.8 M | -25.3 M | -294 M | 66 M | 43.8 M | - | - | - | - | - | - | - |
Revenue |
797 M | 792 M | 750 M | 767 M | 745 M | 551 M | 388 M | 250 M | - | - | - | - | - | - | - |
Cost of Revenue |
57.6 M | 48.2 M | 66.9 M | 65.1 M | 46.7 M | 29.6 M | 14 M | 6.04 M | - | - | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | 521 M | 374 M | 243 M | - | - | - | - | - | - | - |
Operating Income |
87.5 M | 65.8 M | -27 M | 1.74 M | 13.4 M | -276 M | 140 M | 77.3 M | - | - | - | - | - | - | - |
Interest Expense |
718 K | -2.66 M | -4.01 M | - | - | 22 K | -2.97 M | -7 K | - | - | - | - | - | - | - |
EBITDA |
173 M | 135 M | 80.7 M | 55.9 M | 47.9 M | -257 M | 153 M | 87.1 M | - | - | - | - | - | - | - |
Operating Expenses |
- | - | - | - | - | 797 M | 235 M | 166 M | - | - | - | - | - | - | - |
General and Administrative Expenses |
114 M | 118 M | 126 M | 145 M | 155 M | 461 M | 14.7 M | 8.36 M | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement GoodRx Holdings
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
339 M | 341 M | 347 M | 357 M | 379 M | 380 M | 376 M | 390 M | 413 M | 412 M | 412 M | - | 413 M | 412 M | 415 M | - | 411 M | 408 M | 406 M | - | 241 M | 230 M | 230 M | - | 227 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
8.54 M | 1.17 M | 1.12 M | 12.8 M | 11.1 M | 3.96 M | 6.69 M | -1.01 M | -38.5 M | 58.8 M | -3.29 M | - | -41.7 M | -1.42 M | 12.3 M | - | -18.1 M | 31.1 M | 1.67 M | - | -50 M | 27.3 M | 27.3 M | - | 19.6 M | 19.6 M | 11.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
200 M | 194 M | 196 M | 203 M | 203 M | 195 M | 201 M | 198 M | 180 M | 190 M | 184 M | - | 187 M | 192 M | 203 M | - | 195 M | 177 M | 160 M | - | 140 M | 123 M | 133 M | - | 102 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
21 M | 20.2 M | 13.4 M | 13.4 M | 13.4 M | 11.7 M | 11.9 M | 12.5 M | 18.7 M | 16.3 M | 16.7 M | - | 17.4 M | 18 M | 12.3 M | - | 11.3 M | 11.1 M | 10.4 M | - | 7.54 M | 6.82 M | 6.02 M | - | 3.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
23.6 M | 14 M | 14.6 M | 26.8 M | 23.4 M | 20.4 M | 19.9 M | 7.38 M | -38.3 M | 18.3 M | 11.3 M | - | -15.7 M | -4.05 M | 19.8 M | - | 7 M | -351 K | -5 M | - | -61.7 M | 41.7 M | 43.7 M | - | 37.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
625 K | - | - | 694 K | - | -2.66 M | - | - | -2.2 M | - | -1.81 M | - | - | - | - | - | - | - | - | - | -1 K | 16 K | 5 K | - | 4 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
45.9 M | 35.8 M | 36.1 M | 46.5 M | 44.3 M | 37.9 M | 36.8 M | 23.3 M | -5.31 M | 34.4 M | 26.2 M | - | -1.76 M | 9.27 M | 31.1 M | - | 17.2 M | 8.02 M | 363 K | - | -56.5 M | 46.3 M | 48 M | - | 41.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
24.8 M | 26.8 M | 32 M | 28.4 M | 29.6 M | 25.6 M | 27.6 M | 41.1 M | 35.3 M | 30.2 M | 29.6 M | - | 49.5 M | 34.7 M | 31.9 M | - | 35.9 M | 39.6 M | 43.8 M | - | 108 M | 6.33 M | 5.89 M | - | 4.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company GoodRx Holdings (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Health information services industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B |  USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
OptimizeRx Corporation
OPRX
|
$ 9.34 | -1.37 % | $ 173 M | USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B | USA |
 |
10x Genomics
TXG
|
$ 62.88 | -3.34 % | $ 7.84 B | USA |
 |
Veeva Systems
VEEV
|
$ 306.1 | -0.1 % | $ 50.1 B | USA |
 |
SCWorx Corp.
WORX
|
$ 1.31 | -5.76 % | $ 9.53 M | USA |
 |
Zhongchao
ZCMD
|
$ 0.94 | -5.99 % | $ 3.21 M |  China |
 |
HealthStream
HSTM
|
$ 28.69 | -0.14 % | $ 861 M | USA |
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
So-Young International
SY
|
$ 2.0 | 0.5 % | $ 156 M | China |
 |
American Well Corporation
AMWL
|
$ 12.0 | -3.73 % | $ 193 M | USA |
 |
Evolent Health
EVH
|
$ 4.79 | 1.7 % | $ 547 M | USA |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
Health Catalyst
HCAT
|
$ 1.46 | -3.31 % | $ 102 M | USA |
 |
HealthEquity
HQY
|
$ 103.68 | 1.53 % | $ 8.93 B | USA |
 |
Omnicell
OMCL
|
$ 35.87 | -3.96 % | $ 1.65 B | USA |
 |
Progyny
PGNY
|
$ 36.44 | 1.35 % | $ 3.11 B | USA |
 |
Schrödinger
SDGR
|
$ 32.42 | -2.89 % | $ 2.38 B | USA |
 |
Teladoc Health
TDOC
|
$ 8.96 | -0.28 % | $ 1.58 B | USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Phreesia
PHR
|
$ 13.15 | 1.94 % | $ 786 M | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
Premier
PINC
|
- | - | $ 2.33 B | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |